ADC Therapeutics SA
As of Oct 22, 2026, ADC Therapeutics SA is in Stage 1, the basing phase, now in week 2 (since Oct 12, 2026). It closed at $1.60, 67.2% below its 52-week high and below its 200-day average, which is falling.
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ADCT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ADCT among Drug Manufacturers - Specialty & Generic64th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …64 | ADCT | Stage 1 · wk 2 | 18 | +22.1% |
ADC Therapeutics SA: quick answers
What stage is ADC Therapeutics SA in?
As of Oct 22, 2026, ADC Therapeutics SA (ADCT) is in Stage 1, the basing phase. It entered Stage 1 on Oct 12, 2026 and is in week 2. What the four stages mean
Is ADC Therapeutics SA in an uptrend?
Not yet. ADC Therapeutics SA is in Stage 1, a base that can come before an uptrend. It trades 37.1% below its 200-day average, which is falling.
How far is ADC Therapeutics SA from its 52-week high?
ADC Therapeutics SA closed at $1.60 on Oct 22, 2026, 67.2% below its 52-week high of $4.88. Its 52-week low is $0.96.
How has ADC Therapeutics SA performed over the past year?
As of Oct 22, 2026, ADC Therapeutics SA is down 61.3% over the past year and down 54.5% so far in 2026.
Which sector and industry is ADC Therapeutics SA in?
ADC Therapeutics SA is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.